At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
pemetrexeddrug
Likely dose
pemetrexed 500 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid
In Brief
A Phase 2 clinical trial evaluating pemetrexed for Non-small Cell Lung Cancer and 2 related conditions. Completed, enrolled 31 participants across 3 sites in 3 countries.
Detailed Summary
This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Mesothelioma, Lung Neoplasms
CountriesDenmark, Germany, Spain
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartDec 2006
Primary CompletionMar 2009
TodayJul 2026
First PostedApr 20, 2006
Enrollment StartDec 1, 2006
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.2 years ago
Interventions
pemetrexeddrug
500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles